Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
29 August 2025 (07:00 - 18:00)
Organised by: 
About the speaker
(United States of America)
5 More presentations in this session
Professor M. Mamas (Keele, GB)
Doctor N. Kruger (Boston, US)
Access the full session
The Event
ESC Congress 2025
29 August - 1 September 2025
You may be interested in
Congress Session
